Payment overview · 2025
General Payments
$335.51
19 reported records · 7 companies
Healthcare provider profile · identity verified
Ayman Karkoutly, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LUBBOCK, TX · NPI 1477583052
Verified facts
What the public records show
CMS Open Payments records show Ayman Karkoutly, M.D. received $335.51 in general payments during 2025 across 19 reported records.
Medtronic, Inc. accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$94.19 | 28.1% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.70 | 23.8% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $64.72 | 19.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.04 | 9.6% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $29.55 | 8.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.61 | 5.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.70 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $335.51 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $79.70 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $48.69 | 3 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| Philips Laser System Normalized: philips laser system |
Device | Philips North America LLC | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| EVERFLEX PROTEGE EVERFLEX Normalized: everflex protege everflex |
Device | Medtronic, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ranolazine Er | Ranolazine | 960 | 254 |
| Metoprolol Tartrate | Metoprolol Tartrate | 900 | 239 |
| Clopidogrel | Clopidogrel Bisulfate | 783 | 214 |
| Furosemide | Furosemide | 513 | 158 |
| Metoprolol Succinate | Metoprolol Succinate | 510 | 139 |
| Potassium Chloride | Potassium Chloride | 425 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 69 |
| Simvastatin | Simvastatin | 228 | 66 |
| Pentoxifylline | Pentoxifylline | 227 | 59 |
| Carvedilol | Carvedilol | 212 | 62 |
| Digoxin | Digoxin | 212 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 59 |
| Eliquis | Apixaban | 203 | 45 |
| Amiodarone Hcl | Amiodarone Hcl | 175 | 53 |
| Meloxicam | Meloxicam | 172 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 154 | 47 |
| Lisinopril | Lisinopril | 151 | 48 |
| Clonidine Hcl | Clonidine Hcl | 150 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 47 |
| Metformin Hcl | Metformin Hcl | 124 | 41 |
| Gabapentin | Gabapentin | 111 | 34 |
| Nifedipine Er | Nifedipine | 108 | 32 |
| Ezetimibe | Ezetimibe | 97 | 26 |
| Losartan Potassium | Losartan Potassium | 88 | 26 |
| Atenolol | Atenolol | 86 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 18 |
| Glipizide | Glipizide | 65 | 18 |
| Celecoxib | Celecoxib | 62 | 14 |
| Montelukast Sodium | Montelukast Sodium | 61 | 17 |
| Brilinta | Ticagrelor | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 15 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Spironolactone | Spironolactone | 53 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 12 |
| Allopurinol | Allopurinol | 51 | 14 |
| Propafenone Hcl | Propafenone Hcl | 51 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 50 | suppressed |
| Captopril | Captopril | 48 | 13 |
| Jardiance | Empagliflozin | 48 | 17 |
| Sotalol | Sotalol Hcl | 48 | 12 |
| Cephalexin | Cephalexin | 47 | 39 |
| Entresto | Sacubitril/Valsartan | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Omeprazole | Omeprazole | 42 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 14 |
| Meclizine Hcl | Meclizine Hcl | 37 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 22 |
| Nitroglycerin | Nitroglycerin | 36 | 18 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Prednisone | Prednisone | 28 | 12 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Multaq | Dronedarone Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.51 · 19 records | Medtronic, Inc. | CAPVAXIVE, EVERFLEX PROTEGE EVERFLEX, FARXIGA, FUROSCIX, HAWKONE, IN.PACT ADMIRAL, JARDIANCE, LATITUDE Communicator Power Supply, LOKELMA, Philips Laser System, VERQUVO, WINREVAIR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error